Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. May 5, 2024; 15(2): 91591
Published online May 5, 2024. doi: 10.4292/wjgpt.v15.i2.91591
Published online May 5, 2024. doi: 10.4292/wjgpt.v15.i2.91591
Treatment endpoints in ulcerative colitis: Does one size fit all?
Nikola Mitrev, Viraj Kariyawasam, Department of Gastroenterology, Blacktown Hospital, Blacktown 2148, NSW, Australia
Nikola Mitrev, Viraj Kariyawasam, Blacktown/Mt Druitt Clinical School, University of Western Sydney, Blacktown 2148, NSW, Australia
Nikola Mitrev, Department of Gastroenterology, Wollongong Hospital, Loftus St, Wollongong 2500, NSW, Australia
Author contributions: Mitrev N contributed to research and initial write up of the manuscript, Kariyawasam V contributed to research and editing of the manuscript.
Conflict-of-interest statement: All authors declare no conflict-of-interest in the write up of this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nikola Mitrev, BSc, FRACP, MBBS, MPhil, Doctor, Department of Gastroenterology, Blacktown Hospital, 18 Blacktown Road, Blacktown 2148, NSW, Australia. nikola.m@hotmail.com
Received: December 31, 2023
Revised: February 28, 2024
Accepted: April 10, 2024
Published online: May 5, 2024
Processing time: 114 Days and 19.2 Hours
Revised: February 28, 2024
Accepted: April 10, 2024
Published online: May 5, 2024
Processing time: 114 Days and 19.2 Hours
Core Tip
Core Tip: Recently, more stringent treatment endpoints have emerged such as histologic remission and functional gut barrier healing, which may be better predictors of clinically important outcomes compared to mucosal healing. However, pursuing deeper levels of remission in ulcerative colitis patients can have risks. Treatment endpoints in ulcerative colitis should be set with two thresholds, minimum and ideal endpoints to be achieved. Endpoints also need to be appropriate for both the follow up timeframe and the treatment selected. Individual patient circumstances need to be taken into account in selecting endpoints, as at times relaxed treatment endpoints are appropriate.